Anti-CD3epsilon antibodies
AssigneeWuxi Biologics Ireland Limited
InventorsJing Li, Qin Mei
Life of this patent
Estimating the term…
Abstract
The present disclosure provides isolated monoclonal anti-CD3epsilon antibodies or antigen-binding fragments thereof comprising one or more heavy chain CDR sequences selected from the group consisting of: SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 47, and/or one or more kappa light chain CDR sequences selected from the group consisting of: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the use thereof.
Claims19
An isolated antibody or an antigen-binding fragment thereof, comprising:
- a) heavy chain CDR sequences comprising SEQ ID NO:
- 7, SEQ ID NO:
- 9, and SEQ ID NO:
- 11;
- and kappa light chain CDR sequences comprising SEQ ID NO:
- 8, SEQ ID NO:
- 10, and SEQ ID NO:
- 12;
- b) heavy chain CDR sequences comprising SEQ ID NO:
- 1, SEQ ID NO:
- 3, and SEQ ID NO:
- 5;
- and kappa light chain CDR sequences comprising SEQ ID NO:
- 2, SEQ ID NO:
- 4, and SEQ ID NO:
- 6;
- c) heavy chain, CDR sequences comprising SEQ ID NO:
- 13, SEQ ID NO:
- 15, and SEQ ID NO:
- 17;
- and kappa light chain CDR sequences comprising SEQ ID NO:
- 14, SEQ ID NO:
- 16, and SEQ ID NO:
- 18;
- d) heavy chain CDR sequences comprising SEQ ID NO:
- 19, SEQ ID NO:
- 21, and SEQ ID NO:
- 23;
- and kappa light chain CDR sequences comprising SEQ ID NO:
- 20, SEQ ID NO:
- 22, and SEQ ID NO:
- 24;
- e) heavy chain CDR sequences comprising SEQ ID NO:
- 25, SEQ ID NO:
- 27, and SEQ ID NO:
- 29;
- and kappa light chain CDR sequences comprising SEQ ID NO:
- 26, SEQ ID NO:
- 28, and SEQ ID NO:
- 30;
- f) heavy chain CDR sequences comprising SEQ ID NO:
- 31, SEQ ID NO:
- 33, and SEQ ID NO:
- 35;
- and kappa light chain CDR sequences comprising SEQ ID NO:
- 32, SEQ ID NO:
- 34, and SEQ ID NO:
- 36;
- g) heavy chain CDR sequences comprising SEQ ID NO:
- 37, SEQ ID NO:
- 39, and SEQ ID NO:
- 41;
- and kappa light chain CDR sequences comprising SEQ ID NO:
- 38, SEQ ID NO:
- 40, and SEQ ID NO:
- 42;
- or
- h) heavy chain CDR sequences comprising SEQ ID NO:
- 43, SEQ ID NO:
- 45, and SEQ ID NO:
- 47;
- and kappa light chain CDR sequences comprising SEQ ID NO:
- 44, SEQ ID NO:
- 46, and SEQ ID NO:
- 48.
Dependencies are inferred from the claim text.